Expression of the peroxisome proliferator-activated receptors-α, -β, and -γ in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival

被引:19
作者
Davidson, Ben [1 ,2 ]
Hadar, Rivka [3 ]
Stavnes, Helene Tuft [1 ]
Trope, Ciaes G. [2 ,4 ]
Reich, Reuven [3 ]
机构
[1] Norwegian Radium Hosp, Div Pathol, Rikshosp, Med Ctr, N-0310 Oslo, Norway
[2] Univ Oslo, Fac Med, Fac Div, Radiumhosp, N-0316 Oslo, Norway
[3] Hebrew Univ Jerusalem, Dept Pharmacol & Expt Therapeut, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel
[4] Norwegian Radium Hosp, Gynecol Oncol Sect, Div Obstet & Gynecol, Rikshosp,Med Ctr, N-0310 Oslo, Norway
关键词
PPAR; Ovarian carcinoma; Serous effusions; Chemotherapy; Survival; MESSENGER-RNA EXPRESSION; TRANSCRIPTION FACTOR; CLINICAL ROLE; CANCER; PPAR; CYCLOOXYGENASE-2; PROGRESSION; ISOFORMS; MARKER; PEA3;
D O I
10.1016/j.humpath.2008.09.019
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Peroxisome proliferator-activated receptors regulate lipid metabolism, affecting inflammation and cancer. The present study analyzed the anatomical site-related expression and prognostic role of peroxisome proliferator-activated receptors in ovarian carcinoma. Fresh-frozen effusions (n = 79), primary carcinomas (n = 44), and solid metastases (n = 16) were studied for peroxisome proliferator-activated receptor-alpha, -beta and -gamma messenger RNA expression using reverse transcriptase polymerase chain reaction. Peroxisome proliferator-activated receptor-gamma messenger RNA expression was further assessed in 60 tumors (30 effusions, 20 primary carcinomas, 10 metastases) using in situ hybridization. Peroxisome proliferator-activated receptor-gamma protein expression was immunohistochemically analyzed in 160 effusions. All peroxisome proliferator-activated receptors were expressed in most tumors at all anatomical sites using reverse transcriptase polymerase chain reaction, but peroxisome proliferator-activated receptor-alpha (P =.004) and peroxisome proliferator-activated receptor-beta (P = .002) messenger RNA levels were higher in effusions compared with primary carcinomas and solid metastases. In situ hybridization localized peroxisome proliferator-activated receptor-gamma messenger RNA to carcinoma cells in both effusions and solid lesions. Peroxisome proliferator-activated receptor-gamma protein was detected in carcinoma cells in 102 of 160 (64%) effusions. Higher effusion messenger RNA levels of all peroxisome proliferator-activated receptors were associated with less favorable response to chemotherapy at diagnosis (P = .009). In univariate survival analysis, higher messenger RNA expression of all peroxisome proliferator-activated receptors was associated with poor progression-free (P = .045) and overall (P = .014) survival. Higher peroxisome proliferator-activated receptor-gamma protein expression was similarly associated with poor overall survival for the entire cohort (P = .046) and for patients with disease recurrence effusions (P = .009). Peroxisome proliferator-activated receptors were not independent predictors of survival in Cox multivariate analysis. Peroxisome proliferator-activated receptor members are frequently expressed in ovarian carcinoma, with upregulated expression in effusions. Peroxisome proliferator-activated receptor expression in effusions is associated with poor response to chemotherapy at disease recurrence and poor survival, suggesting a role in tumor biology at this unique microenvironment. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:705 / 713
页数:9
相关论文
共 28 条
[1]   Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[2]   An immunohistochemical perspective of PPARβ and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours [J].
Ahmed, N. ;
Riley, C. ;
Quinn, M. A. .
BRITISH JOURNAL OF CANCER, 2008, 98 (08) :1415-1424
[3]  
*CANC REG NORW, 2006, CANC NORW 2005
[4]   High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma [J].
Davidson, B ;
Goldberg, I ;
Gotlieb, WH ;
Kopolovic, J ;
Ben-Baruch, G ;
Nesland, JM ;
Berner, A ;
Bryne, M ;
Reich, R .
CLINICAL & EXPERIMENTAL METASTASIS, 1999, 17 (10) :799-808
[5]   Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies -: Evaluation of five epithelial markers [J].
Davidson, B ;
Risberg, B ;
Kristensen, G ;
Kvalheim, G ;
Emilsen, E ;
Bjåmer, A ;
Berner, A .
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1999, 435 (01) :43-49
[6]   The role of desmin and N-cadherin in effusion cytology - A comparative study using established markers of mesothelial and epithelial cells [J].
Davidson, B ;
Nielsen, S ;
Christensen, J ;
Asschenfeldt, P ;
Berner, A ;
Risberg, B ;
Johansen, P .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (11) :1405-1412
[7]   Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome [J].
Davidson, B ;
Risberg, B ;
Goldberg, I ;
Nesland, JM ;
Berner, A ;
Tropé, CG ;
Kristensen, GB ;
Bryne, M ;
Reich, R .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (12) :1493-1500
[8]  
Davidson B, 2001, CLIN CANCER RES, V7, P551
[9]  
Davidson B, 2003, CLIN CANCER RES, V9, P1412
[10]   The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions [J].
Davidson, B ;
Goldberg, I ;
Tell, L ;
Vigdorchik, S ;
Baekelandt, M ;
Berner, A ;
Kristensen, GB ;
Reich, R ;
Kopolovic, J .
CLINICAL & EXPERIMENTAL METASTASIS, 2004, 21 (03) :191-199